**Flavivirus replication breakthrough**

Flaviviruses cause several debilitating and often fatal diseases including hepatitis, West Nile disease and dengue. It\'s estimated that more than 50 million cases of the potentially fatal dengue occur in humans annually, mainly in tropical and subtropical climes. The molecular biology of the flaviviruses (positive-strand RNA viruses) is poorly understood, which has hampered the development of antivirals and vaccines for flaviviral diseases. Researchers, led by Andrea Garmanik, have just reported a breakthrough in understanding how the dengue virus replicates. The viral RNA-dependent RNA polymerase specifically recognizes a stem-loop structural feature of the viral RNA from the mass of host cell RNAs. This stem-loop is brought close to the initation site for RNA replication by circularization of the genome. The team hope that these insights into dengue virus replication will lay the groundwork for the effective design of antiviral drugs. *Genes Dev*.

**A moratorium on childrens parties**

Authorities in Sarawak, a large state on the island of Borneo, Malaysia have asked parents to cancel childrens gatherings following a renewed outbreak of hand, foot and mouth disease. This viral infection has afflicted more than 12,000 children so far this year, following two previous outbreaks in January and May. Typical symptoms include fever, mouth and throat ulcers, and blisters on the hands and feet. So far, no fatalities have been recorded in this latest outbreak although the disease has claimed the lives of 11 children in other outbreaks this year. In a bid to prevent further spread of the disease, the authorities have temporarily closed two kindergartens in one of the worst-affected areas. The virus that causes the disease, Enterovirus 71, has been detected in cyclical waves of infection that occur every 3 years in this locale. **ProMED mail**

**Architect fined over** ***Legionella*** **outbreak**

An architect in Cumbria, UK, has been cleared of the manslaughter of five people after a trial to prosecute her for culpability in a *Legionella* outbreak that left 170 people ill and five people dead. The outbreak was traced to a faulty air-conditioning unit in a council building in Barrow, UK. A contract that specified regular health and safety checks for the cooling towers of the air-conditioning unit was cancelled by Gillian Beckingham, the architect, but she categorically denied knowing that the crucial contract had been cancelled. She also added that she had never received any health and safety training from Barrow Council. Beckingham was fined £15,000 for a breach of the Health and Safety at Work act, with the local council fined £125,000 for a breach of the same act, bringing the case to a close. **BBC**

**Funding injection for AIDS vaccines**

Just weeks after Warren Buffett boosted the coffers of the Bill and Melinda Gates Foundation (BMGF) with an enormous donation of ∼US\$31 billion, the BMGF has pledged US\$287 million in research grants aimed at developing a HIV vaccine. This grant, collectively the largest to date from the foundation to HIV/AIDS research, will be split among an international consortium of 16 teams of vaccine researchers. The BMGF stipulated that all the grant recipients sign an agreement to openly share their data, in the hope that fruitful collaborations will culminate in the speedy delivery of a successful vaccine candidate(s). The vaccine effort has been ongoing for many years, in the hope that the success stories achieved using the vaccines for smallpox, polio and other viruses can be repeated to tackle the HIV crisis. Currently more than 40 million people are living with HIV and more than 25 million deaths from AIDS have been recorded since the syndrome was first described in 1981. With 14,000 new infections every day, advances in prevention and treatment are not enough to stem the spread of the virus. A vaccine is still the best long-term solution to the HIV pandemic. The research grants are being used to fund a diverse set of projects, from developing traditional and synthetic vaccines that will induce a neutralizing antibody response to using the smallpox and other viruses as prototype HIV vaccine vectors. **BMGF**

**Unwelcome return for polio**

The spectre of polio still hangs over people worldwide, especially those who have never been immunized against this potentially paralysing disease. In Namibia, which had been polio-free since 1995, there have been 19 confirmed cases and 150 suspected cases since June of this year. Bruce Alyward from the WHO cautioned that "there are bigger immunization gaps than at any time in the last 25 years." With natural infections disappearing and vaccination rates dropping in countries that have eradicated the disease, conditions are ripe for a new wave of infections. Dr. Alyward called for countries to vaccinate people early and to ensure that surveillance was sufficient for the early detection of any outbreaks. **WHO/BBC**

**Genomics explains Chikungunya outbreak**

Chikungunya, a mosquito-borne viral disease that was first described in Tanzania, Africa in 1952, is estimated to have infected 110,000 people since March 2005 in La Réunion, with at least 200 chikungunya-related deaths during this period. Symptoms include myalgia, arthralgia, fever, headache and rash. Chikungunya virus was formerly confined to Africa, India and south-east Asia and has only recently emerged in the islands of the South Pacific. Now, genomic sequencing of six clinical La Réunion chikungunya viral isolates and partial glycoprotein E1 sequences from a further 127 patients on the island has shed some light on this outbreak. The authors, writing in *PloS Medicine*, report that there are unique features of the outbreak isolates, including one change in the envelope glycoprotein that was present in over 90% of the isolates. This mutation might have contributed to virus emergence through adaptation to the mosquito vector. ***PloS Medicine***

**Chicken virus vaccine hope**

Researchers using Newcastle disease virus (NDV) --- an economically important negative-strand RNA virus that lethally infects chickens --- as a surrogate vaccine vector have been awarded a grant of more than US\$4 million by the National Institutes of Health to continue research into using NDV as a vaccine vector to tackle SARS. Promising trials of a candidate SARS vaccine in monkeys were presented at a conference in July. Team leader Siba Samal commented that NDV has several features that make it attractive as a vaccine vector, including the fact that "NDV replicates in species other than poultry, but not enough to cause disease." With reverse-genetics techniques in place for NDV, and nine serotypes available for engineering as vaccines, this virus might be a suitable vaccine vector for not only SARS but H5N1 avian influenza as well. **Newswise**

**Ferreting around for pandemic clues**

Using a ferret model that parallels the transmission of influenza in humans, researchers from the CDC have now shown that, contrary to concerns, hybrid human--avian influenza viruses are usually benign. Since 1997, the H5N1 virus has infected at least 232 people, mostly in Asia, of whom 134 have died. So far, the H5N1 form of avian influenza has not been readily transmitted between humans but the worry is that this virus will mutate and cause a pandemic. Using reverse genetics, the CDC team produced hybrid influenza strains that mixed genes from an H3N2 human seasonal \'flu strain with the deadly avian H5N1 strain and used these to infect ferrets that were housed in adjacent cages, to try and mimic the spread of \'flu. The reassortant viruses either replicated well but did not transmit between ferrets, or failed both to replicate and to spread. Simple reassorting of influenza virus segments therefore seems unlikely to result in a \'flu pandemic, with other mutations probably needed to enable H5N1 to spread rapidly among humans. This model system "\...is a good tool to assess the potential of H5N1 viruses to cause a pandemic in the future," said Jacqueline Katz, who led the study. Albert Osterhaus commented that we can be a \'bit relieved\' but Julia Gerberding, director of the CDC cautioned that "we are not out of the woods on pandemic preparedness yet." **NY Times/** ***PNAS***

**DDT comeback for malaria**

Controlled spraying of the infamous pesticide dichlorodiphenyl-trichloro ethane (DDT) is poised to make a comeback in the battle against malaria. Malaria kills up to 1 million people annually, 90% of whom live in sub-Saharan Africa. In 1939, Dr. Paul Müller produced DDT and found that it killed many insects and beetles, for which he was awarded a Nobel prize. Although effectively used in the USA to combat the disease in the late 1940s, DDT was banned in the 1970s over environmental concerns that the chemical was entering the food chain. Now this infamous insecticide will be deployed against malaria in minimal and controlled spraying of homes in the hope of saving lives. ***Nature Med***.

**Antiviral seaweed extract**

A team led by John Schiller has identified carrageenan, a simple food and cosmetic thickening agent, as a potent inhibitor of the Human papilloma virus (HPV) that is associated with cervical cancer. It\'s not the first antiviral application for carrageenan, which is derived from seaweed. This algal food additive can inhibit herpes simplex viruses (HSV) and some strains of HIV *in vitro*, but genital HPVs are one thousand times more susceptible than HSV to the compound. Carrageenan prevent HPV virions from binding to cells, thereby stopping infection in its tracks. As Carraguard --- a microbicide containing carrageenan that was designed to fight HIV transmissions --- is currently being tested, it\'s hoped that clinical trials might quickly establish the efficacy of the same gel against HPV. Although HPV vaccines are currently on their way to the clinic, they would be far more expensive than microbicides. ***PloS Pathogens***

**Outbreak news**

***Lassa fever.*** German authorities reported a single, laboratory-confirmed case of Lassa fever to the WHO in late July. The afflicted individual flew into Frankfurt, Germany from Sierra Leone, became ill once he arrived and was treated in isolation. A contact tracing exercise for his fellow passengers is ongoing although the likelihood of transmission is low.

***Avian influenza.*** Indonesian authorities have confirmed their fifty-fourth case of human avian influenza. The affected individual, who was from east Jakarta, developed symptoms on the 24th June and later died on the 12th July. The source of the infection is the subject of an ongoing investigation. Out of the 54 avian influenza cases in Indonesia, 42 have been fatal.

*In the News was compiled with the assistance of David Ojcius, University of California, Merced, USA. David\'s links to infectious disease news stories can be accessed on Connotea (*<http://www.connotea.org>*), under the username ojcius*.
